Biological and Environmental Research Ontology

Last uploaded: December 23, 2022
Id http://purl.obolibrary.org/obo/NCIT_C61502
http://purl.obolibrary.org/obo/NCIT_C61502
Preferred Name

Mapatumumab
Definitions
A fully human agonistic monoclonal antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor-1 (TRAIL-R1) with apoptosis promoting and potential antitumor activities. TRAIL-R1 is a cell surface receptor expressed on many malignant cell types. Mapatumumab selectively binds to and activates the TRAIL cell receptor, thereby inducing apoptosis and reducing tumor growth.
Type http://www.w3.org/2002/07/owl#Class

All Properties

definition

A fully human agonistic monoclonal antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor-1 (TRAIL-R1) with apoptosis promoting and potential antitumor activities. TRAIL-R1 is a cell surface receptor expressed on many malignant cell types. Mapatumumab selectively binds to and activates the TRAIL cell receptor, thereby inducing apoptosis and reducing tumor growth.
label
Mapatumumab
prefLabel
Mapatumumab
Legacy Concept Name
Mapatumumab
in_subset
Preferred_Name
Mapatumumab
Is_Value_For_GDC_Property
Display_Name
Mapatumumab
Maps_To
Mapatumumab
PDQ_Open_Trial_Search_ID
486626
Has_Target
UMLS_CUI
C1665688
FDA_UNII_Code
WZ1025JPGR
prefixIRI
NCIT:C61502
NCI_Drug_Dictionary_ID
486626
Contributing_Source
CTRP
FDA
subClassOf
code
C61502
type
ALT_DEFINITION
A substance being studied in the treatment of some types of cancer. It binds to a protein called TRAIL R1 on the surface of some tumor cells. This may kill the tumor cells. Anti-TRAIL R1-mAb is a type of monoclonal antibody.
PDQ_Closed_Trial_Search_ID
486626
Semantic_Type
Amino Acid, Peptide, or Protein
Pharmacologic Substance
Immunologic Factor
CAS_Registry
658052-09-6
Add comment
Add proposal
Delete Subject Author Type Created
No notes to display